| Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label … SD Schwartz, CD Regillo, BL Lam, D Eliott, PJ Rosenfeld, NZ Gregori, ... The Lancet 385 (9967), 509-516, 2015 | 1464 | 2015 |
| Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 CD Regillo, DM Brown, P Abraham, H Yue, T Ianchulev, S Schneider, ... American journal of ophthalmology 145 (2), 239-248. e5, 2008 | 1130 | 2008 |
| Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results JA Haller, F Bandello, R Belfort Jr, MS Blumenkranz, M Gillies, J Heier, ... Ophthalmology 118 (12), 2453-2460, 2011 | 873 | 2011 |
| Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration W Chen, D Stambolian, AO Edwards, KE Branham, M Othman, ... Proceedings of the National Academy of Sciences 107 (16), 7401-7406, 2010 | 603 | 2010 |
| Five-year safety and performance results from the Argus II retinal prosthesis system clinical trial L da Cruz, JD Dorn, MS Humayun, G Dagnelie, J Handa, PO Barale, ... Ophthalmology 123 (10), 2248-2254, 2016 | 377 | 2016 |
| A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact OP Gupta, G Shienbaum, AH Patel, C Fecarotta, RS Kaiser, CD Regillo Ophthalmology 117 (11), 2134-2140, 2010 | 355 | 2010 |
| Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration AC Ho, BG Busbee, CD Regillo, MR Wieland, SA Van Everen, Z Li, ... Ophthalmology 121 (11), 2181-2192, 2014 | 352 | 2014 |
| Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection ML Nelson, MTS Tennant, A Sivalingam, CD Regillo, JB Belmont, ... Retina 23 (5), 686-691, 2003 | 348 | 2003 |
| Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement AS Hassan, MW Johnson, TE Schneiderman, CD Regillo, PE Tornambe, ... Ophthalmology 106 (10), 1900-1907, 1999 | 336 | 1999 |
| A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome EYJ Ng, BP Connolly, JA McNamara, CD Regillo, JF Vander, W Tasman Ophthalmology 109 (5), 928-934, 2002 | 299 | 2002 |
| The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial PA Campochiaro, DM Marcus, CC Awh, C Regillo, AP Adamis, ... Ophthalmology 126 (8), 1141-1154, 2019 | 279 | 2019 |
| Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations KB Freund, JF Korobelnik, R Devenyi, C Framme, J Galic, E Herbert, ... Retina 35 (8), 1489-1506, 2015 | 279 | 2015 |
| Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients DM Brown, CD Regillo American journal of ophthalmology 144 (4), 627-637. e2, 2007 | 276 | 2007 |
| Long-term results from an epiretinal prosthesis to restore sight to the blind AC Ho, MS Humayun, JD Dorn, L Da Cruz, G Dagnelie, J Handa, ... Ophthalmology 122 (8), 1547-1554, 2015 | 275 | 2015 |
| A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome BP Connolly, EYJ Ng, JA McNamara, CD Regillo, JF Vander, W Tasman Ophthalmology 109 (5), 936-941, 2002 | 274 | 2002 |
| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 266 | 2022 |
| Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab DR Fintak, GK Shah, KJ Blinder, CD Regillo, J Pollack, JS Heier, ... Retina 28 (10), 1395-1399, 2008 | 266 | 2008 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 244 | 2022 |
| Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration BL Yaspan, DF Williams, FG Holz, CD Regillo, Z Li, A Dressen, ... Science translational medicine 9 (395), eaaf1443, 2017 | 187 | 2017 |
| Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis GK Shah, JD Stein, S Sharma, A Sivalingam, WE Benson, CD Regillo, ... Ophthalmology 107 (3), 486-489, 2000 | 183 | 2000 |
